Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC)

This study investigates whether adding magnesium to the standard chemo-immunotherapy for advanced non-small cell lung cancer (NSCLC) can improve treatment outcomes. Magnesium is important for immune function, and low levels during chemotherapy are common. Participants are randomly assigned to receive either magnesium or a placebo, both as infusions and tablets. Neither the participants nor the doctors know who receives which treatment. The study compares the two groups to see if magnesium helps and how well it is tolerated.

NCT Number	NCT07149649
Lead Sponsor	Swiss Cancer Institute
Conditions	Metastatic NSCLC - Non-Small Cell Lung Cancer
Enrollment	230 participants
Start Date	2026-08
Primary Completion	2031-01-01 (estimated)
Study Completion	2035-03-31 (estimated)
Updated on ClinicalTrials.gov	2026-07-16